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 JCS Advance Online Article. Posted on 5 March 2018
 Summary Statement 
The essential neural protein neurochondrin interacts with the Spinal Muscular Atrophy (SMA) 
protein, SMN, in cell lines and in vivo. This may be relevant to the molecular pathology of SMA. 
Abstract 
Spinal Muscular Atrophy (SMA) is an inherited neurodegenerative condition caused by reduction 
in functional Survival Motor Neurones Protein (SMN). SMN has been implicated in transport of 
mRNA in neural cells for local translation. We previously identified microtubule-dependant mobile 
vesicles rich in SMN and SmB, a member of the Sm family of snRNP-associated proteins, in neural 
cells. By comparing the interactomes of SmB and SmN, a neural-specific Sm protein, we now show 
that the essential neural protein neurochondrin (NCDN) interacts with Sm proteins and SMN in the 
context of mobile vesicles in neurites. NCDN has roles in protein localisation in neural cells, and in 
maintenance of cell polarity. NCDN is required for the correct localisation of SMN, suggesting they 
may both be required for formation and transport of trafficking vesicles. NCDN may have potential 
as a therapeutic target for SMA together with, or in place of, those targeting SMN expression. 
Introduction 
The inherited neurodegenerative disease, Spinal Muscular Atrophy (SMA) is caused by a 
reduction in the amount of functional Survival Motor Neuron (SMN) protein (Lefebvre et al., 
1995). SMA is the leading genetic cause of infant mortality, affecting 1:6000 live births (Monani, 
2005). The recently developed therapy, Spinraza/Nusinersen (Biogen) has been shown to increase 
the level of SMN and improve the symptoms of SMA patients (Corey, 2017; Finkel et al., 2016; 
Passini et al., 2011). Most SMA patients harbour mutations in the SMN1 gene, which produces the 
majority of total SMN protein in cells. In humans, expression from a variable number of copies of 
an additional gene, SMN2, can produce some full-length SMN protein (Lefebvre et al., 1995; 
Lefebvre et al., 1997). The SMN2 gene, unlike SMN1, contains a point mutation in an exon splicing 
enhancer (Lorson and Androphy, 2000; Lorson et al., 1999) resulting in truncation of most of the 
SMN protein produced by SMN2 through skipping of exon 7. The truncated protein produced by 
SMN2 is less stable than full-length SMN and cannot compensate fully for the loss of SMN1 (Le et 
al., 2005; Lorson and Androphy, 2000; Lorson et al., 1999). However, due to the small amounts of 
full length SMN expressed from the SMN2 gene, the number of gene copies can influence the 
severity of SMA, with evidence that five copies of SMN2 may be enough to compensate for loss of 
SMN1 (Campbell et al., 1997; Prior et al., 2004). It is not currently clear how a deficiency of 
functional SMN leads to the specific symptoms of SMA. In particular, the differing sensitivity of cell 
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 types to lowered SMN levels, with motor neurons (MNs) most severely affected, is difficult to 
explain as SMN is an essential protein and complete deletion is lethal at the cellular level (Hsieh-Li 
et al., 2000; Schrank et al., 1997).  
 
SMN localises to nuclear Cajal bodies and gems (Gemini of Cajal bodies (CBs)) (Liu and 
Dreyfuss, 1996) as well as in the cytoplasm and is implicated in a growing number of cellular roles 
in both locations (Hosseinibarkooie et al., 2017; Li et al., 2014; Monani, 2005; Singh et al., 2017; 
Sleeman, 2013; Tisdale and Pellizzoni, 2015). The first to be elucidated was a role in the early, 
cytoplasmic, stages of assembly and maturation of splicing snRNPs (small nuclear 
ribonucleoproteins). Splicing snRNPs are ribonucleoprotein complexes, essential for pre-mRNA 
splicing, comprising an snRNA (small nuclear RNA) core and numerous proteins including a 
heptameric ring containing one copy each of members of the Sm protein family. SMN is part of a 
cytoplasmic complex, also containing the gemin proteins, required for the addition of the Sm 
proteins as a ring around the snRNA core (Li et al., 2014; Liu et al., 1997; Stark et al., 2001; Tisdale 
and Pellizzoni, 2015). The maturation of snRNPs has been shown to be impaired by a deletion in 
SMN (Gabanella et al., 2007; Shpargel and Matera, 2005; Wan et al., 2005; Winkler et al., 2005; 
Zhang et al., 2008), while alterations to pre-mRNA splicing events, proposed to be a downstream 
consequence of this impairment, have been observed in several models of SMA (Custer et al., 
2013; Huo et al., 2014; Zhang et al., 2008). One of the proposed mechanisms for the cell-type 
specificity of SMA is that these alterations of pre-mRNA splicing events affect mRNA transcripts 
that are essential for motor neurons, perhaps preferentially affecting transcripts spliced by the 
minor spliceosome (Boulisfane et al., 2011; Custer et al., 2016; Doktor et al., 2017; Gabanella et 
al., 2007; Zhang et al., 2008). Despite promising results in Drosophila models, however, specific 
transcripts affecting MNs are yet to be conclusively identified (Lotti et al., 2012). 
Another well-established cellular role of SMN is in the trafficking of mature mRNA within 
the cytoplasm, particularly in the axons and neurites of neural cell types. (Akten et al., 2011; 
Custer et al., 2013; Fallini et al., 2016; Fallini et al., 2014; Fallini et al., 2011; Li et al., 2015; Lotti et 
al., 2012; Peter et al., 2011; Rossoll et al., 2003; Rossoll et al., 2002; Todd et al., 2010a; Todd et al., 
2010b; Zhang et al., 2006; Zhang et al., 2003). This is thought to be linked to local translation of 
mRNA into proteins, an important process for neural cells, in particular motor neurones, due to 
the length of their axons (Doyle and Kiebler, 2011; Holt and Schuman, 2013; Huber et al., 2000; 
Kang and Schuman, 1996), making this trafficking role for SMN of particular interest for 
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 understanding the cellular pathology of SMA. SMN co-localises with the mRNA binding proteins 
HuD, IMP1 and hnRNP R and is involved in the localisation of mRNAs to axons (Akten et al., 2011; 
Fallini et al., 2014; Fallini et al., 2011; Rossoll et al., 2003). The cellular structures involved in SMN-
dependent mRNA trafficking are currently unclear, being described as granular (Akten et al., 2011; 
Fallini et al., 2014; Peter et al., 2011; Todd et al., 2010b; Zhang et al., 2006; Zhang et al., 2003) or 
vesicular in nature (Custer et al., 2013; Prescott et al., 2014). 
SMN has also been implicated in many other processes. Some of these involve a role in 
RNP assembly, similar to the canonical role in splicing snRNP production, including assembly of 
both the signal recognition particle and the U7 snRNP required for 3’ processing of histone mRNA 
(Azzouz et al., 2005; Piazzon et al., 2013; Tisdale et al., 2013). Other roles are more diverse and 
include the regulation of cytoskeletal dynamics and endocytosis (Bowerman et al., 2007; Dimitriadi 
et al., 2016; Giesemann et al., 1999; Hao le et al., 2012; Heesen et al., 2016; Hosseinibarkooie et 
al., 2016; Nolle et al., 2011; Oprea et al., 2008; Riessland et al., 2017); enhancement of DNA repair 
(Takaku et al., 2011); transcriptional regulation (Pellizzoni et al., 2001; Zhao et al., 2016; Zou et al., 
2004); stress granule formation (Hua and Zhou, 2004; Zou et al., 2011) and ubiquitin homeostasis 
(Wishart et al., 2014). It is currently unclear whether or how disruption of the many proposed 
roles for SMN contributes to SMA pathogenesis. 
Structures containing the SMN and SmB proteins, alongside Coatomer Gamma are 
trafficked on microtubules (Prescott et al., 2014). Evidence suggesting that SMN/SmB-rich 
structures are vesicular in nature includes their staining with lipophilic dyes in living neural cells, 
their vesicular appearance using correlative fluorescence and electron microscopy (Prescott et al., 
2014), and the interaction of SMN and the Sm proteins with Coatomer proteins, which are 
associated with membrane bound vesicles (Custer et al., 2013; Peter et al., 2011; Prescott et al., 
2014). We have previously identified an interaction between SmB and dynein cytoplasmic 1 heavy 
chain 1 (DYNC1H1), a motor protein required for microtubule transport (Prescott et al., 2014), 
mutation in which can cause a rare, lower extremity dominant SMA (Chen et al., 2017; Ding et al., 
2016; Harms et al., 2010; Harms et al., 2012; Niu et al., 2015; Peeters et al., 2015; Punetha et al., 
2015; Scoto et al., 2015; Strickland et al., 2015; Tsurusaki et al., 2012). SMN has also been shown 
to associate with the membranous Golgi complex (Ting et al., 2012), while mutations in the Golgi-
related protein BICD2 (bicaudal D homolog 2) cause a form of lower extremity dominant SMA 
(Martinez-Carrera and Wirth, 2015; Neveling et al., 2013; Oates et al., 2013; Peeters et al., 2013; 
Rossor et al., 2015; Synofzik et al., 2014).  
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The Sm protein family is implicated in both of the major functions of SMN. The core of 
splicing snRNPs comprises a heptameric ring of proteins around the snRNA, containing SmB/B’, D1, 
D2, D3 E, F and G (Urlaub et al., 2001). SMN is a vital part of the complex required for the 
assembly of this Sm protein ring (Battle et al., 2006; Fischer et al., 2011; Fischer et al., 1997; Liu 
and Dreyfuss, 1996; Meister et al., 2001; Meister and Fischer, 2002; Pellizzoni et al., 2002). Other 
members of the Sm protein family have also been identified, beyond the core proteins usually 
found in splicing snRNPs.  Of particular interest in the context of SMA pathology is SmN (encoded 
by the SNRPN gene), which is expressed in neural tissues (Schmauss et al., 1992) and can replace 
SmB in the heptameric Sm protein ring (Huntriss et al., 1993). The human SmN protein differs from 
SmB’ by 17 amino acids (UniProt Identifiers P63162 and P14678 respectively), and little is known 
about its behaviour other than its incorporation into snRNPs, although the SNRPN gene locus is 
within the paternally imprinted region of the genome critical in Prader-Willi Syndrome (Ozcelik et 
al., 1992). There is growing appreciation that some Sm proteins may ‘moonlight’ in functions 
beyond their presence in splicing snRNPs. In addition to the role of SmB in cytoplasmic trafficking 
vesicles in human cells, in Drosophila SmB and SmD3 are implicated in mRNA localisation 
(Gonsalvez et al., 2010) and SmD1 has a role in miRNA biogenesis (Xiong et al., 2015). With this in 
mind, we applied a proteomic approach in the neural cell line SH-SY5Y to search for interactions 
that could indicate neural specific roles for the SmN protein of relevance for the pathology of 
SMA. 
This proteomic approach led to the identification of Neurochondrin (NCDN) as a novel 
interactor of both SmN and SMN. NCDN is an essential protein predominantly expressed in neural 
tissue and involved in neural outgrowth, synaptic plasticity and moderation of signal transduction 
(Dateki et al., 2005; Francke et al., 2006; Matosin et al., 2015; Pan et al., 2016; Shinozaki et al., 
1999; Shinozaki et al., 1997; Wang et al., 2013; Wang et al., 2009; Ward et al., 2009). Further 
investigation of the relationship between NCDN and SMN suggest that NCDN interacts with SMN 
in the context of mobile cytoplasmic vesicles containing SmB and SmN and is strongly expressed in 
motor neurones. This suggests that NCDN warrants further investigation in the context of SMA 
pathology and may proves useful as a target for future therapy development. 
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Results 
 
SmN exhibits similar behaviour to SmB, localising to cytoplasmic vesicles containing SMN  
 
In order to determine the interactome of the neural-specific Sm protein, SmN, we first 
generated constructs to express fluorescent protein-tagged SmN by amplifying the SmN sequence 
from total RNA from SH-SY5Y cells and cloning it into the pEYFP-C1 and pmCherry-C1vectors. All of 
the Sm fusion proteins studied so far show a steady-state localisation to nuclear Cajal Bodies (CBs) 
and speckles. The Sm proteins SmB, SmD1 and SmE have also previously been shown to exhibit a 
characteristic pathway within the cell on their initial expression, indicative of the snRNP 
maturation pathway (Sleeman and Lamond, 1999), although differences were seen between the 
Sm proteins. To confirm that YFP-SmN localised correctly at steady state to CBs and speckles, and 
to determine where SmN localised during maturation and incorporation into snRNPs, the plasmid 
was transiently expressed in SH-SY5Y neuroblastoma cells, with cells fixed and immunostained at 
24 hour intervals. At 48 and 72 hours after transfection, YFP-SmN predominantly localised to 
speckles and Cajal bodies (CBs, detected with anti-coilin) identically to endogenous Sm proteins 
(detected with Y12 antibody), whereas at 24 hours, YFP-SmN localised predominantly diffusely 
within the cytoplasm, with some accumulation in CBs (Fig 1A, B). This sequential localisation is 
indistinguishable from that previously observed with YFP-SmB in HeLa and MCF-7 cells, though CBs 
were not prominent in the majority of SH-SY5Y cells transiently expressing YFP-SmN.  Equivalent 
results were obtained in SH-SY5Y cells transiently expressing mCherry-SmN (Fig S1). Both YFP-SmN 
and mCherry-SmN are efficiently incorporated into splicing snRNPs, as evidenced by their 
enrichment from whole-cell lysates using antibodies against the characteristic hypermethylated 
Cap structure (2,2,7-trimethylaguanosine) found on snRNAs (Fig 1C). 
To determine whether the similarities between SmN and SmB extend to localisation in 
detergent-sensitive vesicles in the cytoplasm (Prescott et al., 2014), SH-SY5Y cells constitutively 
expressing mCherry-SmN were used for live-cell time-lapse microscopy. Mobile mCherry-SmN foci 
were observed (movie S1). In common with the SmB vesicles, these stained positive with the 
lipophilic dye, BODIPY 493, indicating that they are vesicular in nature (Fig 1D). Finally, to confirm 
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 that the mCherry-SmN vesicles were similar to those previously identified with SmB, SH-SY5Y cells 
constitutively expressing mCherry-SmN were transfected with plasmids to express either GFP-SMN 
or YFP alone.  GFP-SMN co-localised with mCherry-SmN in 83% (11) of SmN-positive vesicles, 
which is statistically significant when compared to 8.4% (4.5) of mCherry-SmN vesicles co-
localising with YFP alone (Fig 1E, F). 
 
Mass Spectrometry reveals similarities between the interactomes of SmN and SmB 
 
As SmN appeared to behave very similarly to SmB in neural cells, it was unclear why neural 
cells express two almost identical proteins. It was decided to investigate whether SmN and SmB 
may have differing roles that could be identified by proteomic analysis. SH-SY5Y cells were 
selected for this analysis as they are easy to culture and amenable to the generation of cell lines 
constitutively expressing FP-tagged proteins, while retaining neural characteristics including the 
expression of neural proteins. They are also human in origin. Proteins interacting with YFP-SmB 
and YFP-SmN were affinity purified using GFP-TRAP (Chromotek) from whole-cell lysates of SH-
SY5Y cell lines constitutively expressing the tagged proteins, with a cell line expressing YFP alone 
as a control for non-specific binding to the tag or bead matrix. Immunoblot analysis using 
antibodies to YFP demonstrated that the enrichment of the tagged proteins was 20X, 23X and 4X 
for YFP-SmN, YFP-SmB and YFP alone respectively (Fig 2A). The affinity purified material was size 
separated using SDS-PAGE and analysed by nLC ESI MS/MS mass spectrometry to identify peptides 
and therefore proteins interacting with YFP-SmB and YFP-SmN. Following removal of likely 
contaminants identified by their interaction with YFP alone, or their previous identification as 
common interactors of GFP-TRAP (Trinkle-Mulcahy et al., 2008), UniProt Biological Process and 
Cellular Component Genome Ontology annotations were used to group identified proteins into 
categories depending on function. These groups were then used to determine whether there were 
differences in possible functions between SmN and SmB (Fig 2B). Numerous proteins previously 
established to interact with Sm proteins were identified including SMN and the gemins as well as 
the methylosome components PRMT5, MEP50 and pICIn, validating our approach (Table S2).  The 
overall proportions of proteins in each category were similar when comparing the interactomes of 
SmN to SmB, though differences were identified at the level of individual proteins. Of particular 
interest in the context of SMA were a number of proteins with potential neural specific roles, 
which were identified in one or both samples. One of these was Neurochondrin (NCDN), a 
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 relatively poorly characterised neural protein, which was identified in the YFP-SmN interactome, 
with 5 unique peptides identified (Fig 2D). 
 
Neurochondrin interacts with SmN, SmB and SMN in cell lines and in vivo 
 
To verify the interaction between Sm proteins and Neurochondrin, a construct expressing 
NCDN-GFP was generated. Affinity purification of NCDN-GFP from whole cell lysates of SH-SY5Y 
cells transiently co-expressing NCDN-GFP and mCherry-SmB demonstrated interaction between 
NCDN-GFP and mCherry-SmB (Fig 3A). To further investigate interactions between NCDN and the 
Sm proteins neural cells, an SH-SY5Y cell line constitutively expressing NCDN-GFP was established. 
Affinity purification of NCDN-GFP from whole cell lysates followed by immunoblot analysis using 
antibodies against endogenous SmN and SmB (Fig 3B) revealed that NCDN-GFP interacts with both 
SmN and SmB. Furthermore, both endogenous SMN and endogenous COP (a coatomer vesicle 
protein) were also revealed to interact with NCDN-GFP, suggesting that NCDN interacts with the 
Sm proteins and SMN in the context of cytoplasmic vesicles. Affinity purification of YFP alone from 
whole cell lysates of an SH-SY5Y cell line constitutively expressing YFP does not result in co-
purification of endogenous SMN, SmB or COP (Fig 3C). To further investigate the interaction 
between SMN and NCDN observed in Fig 3B, a reciprocal experiment was performed using GFP-
Trap to affinity purify GFP-SMN from an SH-SY5Y cell line constitutively expressing GFP-SMN 
(Clelland et al., 2009). Subsequent immunoblot analysis using antibodies to endogenous NCDN 
demonstrated that NCDN co-enriched with GFP-SMN (Fig 3D). To determine whether this 
interaction also occurs between the endogenous proteins at normal expression levels, we first 
immuno-precipitated endogenous SMN from whole cell lysates of SH-SY5Y cells. Immunoblot 
analysis using antibodies to endogenous NCDN (Fig 3D) confirmed that endogenous SMN interacts 
with endogenous NCDN. Moreover, to determine whether this interaction is also present at 
endogenous levels in vivo, and thus of potential relevance to SMA pathology, SMN was immuno-
precipitated from lysates of P8 mouse brain. Again, we confirmed that endogenous SMN interacts 
with endogenous NCDN in vivo (Fig 3E). Together, these results confirm the interaction of SMN 
and NCDN at endogenous levels and in vivo. 
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Neurochondrin co-localises with SmN, SmB and SMN in cytoplasmic vesicles but not nuclear foci 
and is strongly expressed in motor neurones in mouse spinal cord. 
 
To determine the probable cellular location for the interaction between SmN/SmB and 
NCDN, plasmids to express either NCDN-GFP or YFP were transiently transfected into SH-SY5Y cells 
constitutively expressing mCherry-SmN. This revealed that NCDN-GFP, but not YFP alone, 
accumulates in cytoplasmic vesicles containing mCherry-SmN (Fig 4A). Similar results were 
obtained when NCDN-GFP was transiently expressed in SH-SY5Y cells constitutively expressing 
mCherry-SmB (Fig S3). To investigate the probable cellular location of interactions between SMN 
and NCDN, mCherry-SMN was co-expressed with either NCDN-GFP or YFP alone. NCDN-GFP was 
found in cytoplasmic structures enriched in mCherry-SMN (Fig 4B). These data suggest that NCDN 
co-localises with both the Sm proteins and SMN in cytoplasmic vesicles, although NCDN-GFP 
shows an increase diffuse signal compared to the Sm proteins or SMN. Within the nucleus, 
antibodies to endogenous NCDN showed very little nuclear staining, with nuclear foci evident in 
very few cells (≤2%). These foci did not stain with antibodies to either coilin or SMN (Fig 4C) 
indicating that they are neither Cajal bodies nor gems. In sections from murine P5 spinal cord (Fig 
4D,E), NCDN shows robust expression throughout the spinal cord. Interestingly, NCDN was most 
prominently expressed in ChAT-positive motor neurons in the ventral horn of the spinal cord 
(arrows in Fig 4D, enlarged in Fig 4E). This indicates that NCDN is enriched in motor neurons: the 
most relevant cell type for SMA. 
 
NCDN, SMN and Sm protein co-fractionate with coatomer proteins. 
 
To further investigate the possibility that the interaction of NCDN with SMN and the Sm 
proteins occurs within cytoplasmic vesicles, sub-cellular fractionations were performed on both 
parental SH-SY5Y cells and SH-SY5Y cell lines constitutively expressing NCDN-GFP, YFP-SmB, YFP-
SmN or YFP. Sequential centrifugation was used to separate the cells into a nuclear fraction, 
16,000 RCF and 100,000 RCF cytoplasmic pellets and cytosolic supernatant (De Duve, 1971).  
Immunoblotting of these sub-cellular fractions revealed that GFP-NCDN, YFP-SmB and YFP-SmN, 
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 were all enriched in the 100,000 RCF cytoplasmic pellet, along with endogenous SMN and 
coatomer proteins (Fig 5). This fraction would be expected to contain membrane-bound 
structures, such as microsomes and small cytoplasmic vesicles, which would encompass small 
coatomer type endocytic vesicles. Endogenous SmN was also observed to enrich similarly (Fig S4). 
NCDN-GFP shows a larger proportion of protein in the remaining cytosolic supernatant when 
compared to YFP-SmB, YFP-SmN and endogenous SMN, which is in agreement with the sub-
cellular localisations observed (Fig 4). This further supports our hypothesis that the interactions 
between NCDN, SMN and the Sm proteins take place in small cytoplasmic vesicles. 
NCDN is required for the correct sub-cellular localisation of SMN 
 
We have previously documented that reduction of SmB expression results in re-localisation 
of SMN into numerous nuclear structures, probably analogous to gems (Gemini of CBs), and its 
loss from cytoplasmic structures (Prescott et al., 2014). To investigate the requirement for NCDN 
in cytoplasmic SMN localisation, an SH-SY5Y cell line constitutively expressing GFP-SMN (Clelland 
et al., 2009) was transfected with siRNAs targeting NCDN (4 different single siRNAs (Dharmacon) 
and a pooled sample). A reduction in NCDN expression caused an increase in the number of SMN-
positive nuclear foci present in the cell nucleus, as did a reduction of SmB expression (Fig 6A, B). 
Conversely, reduction in SMN expression reduced the number of SMN-positive nuclear foci. The 
use of non-targeting control (siControl) sequences or positive control siRNAs (targeting Lamin A/C) 
had no effect on the number of SMN-positive nuclear foci. The reduction in gene expression, 
assayed by immunoblotting, for each siRNA was typically 40-60% (Fig 6C). This suggests that NCDN 
is required for the correct sub-localisation of SMN. Of potential relevance for SMA pathology, 
depletion of either NCDN or SmB causes GFP-SMN to adopt a sub-cellular localisation reminiscent 
of that shown by GFP-SMN∆7 (Fig 6), a truncated version of SMN that mimics the product of the 
SMN2 gene and is unable to completely substitute for full-length SMN in models of SMA (Le et al., 
2005; Monani et al., 1999; Monani et al., 2000). 
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SMN is required for the correct sub-cellular localisation of NCDN 
 
To investigate whether NCDN requires the SMN protein for its localisation to vesicles in 
neural cells, SH-SY5Y cells were transfected with shRNA constructs previously validated to reduce 
the expression of SMN by an average of 46%, a reduction previously found to cause symptoms 
resembling SMA Type III in mouse models (Jablonka et al., 2000), and carrying a GFP marker to 
unequivocally identify transfected cells (Clelland et al., 2012). Reduction of SMN, monitored by 
quantitation of the number of SMN-positive nuclear foci (Fig 7A,C), reduced the number of 
cytoplasmic foci containing endogenous NCDN (Fig 7A, B). This, together with data in Figure 6, 
suggests that NCDN and SMN are mutually dependent for their incorporation into cytoplasmic 
structures, raising the possibility that the lowered levels of SMN seen in SMA could compromise 
NCDN function. 
NCDN does not co-purify with splicing snRNPs, suggesting it is not involved in snRNP assembly  
 
To investigate whether the interaction between NCDN and SMN could reflect a previously 
unidentified role for NCDN in snRNP assembly, splicing snRNPs were affinity purified from whole 
cells lysates of SH-SY5Y cells constitutively expressing NCDN-GFP using agarose beads coupled to 
antibodies against the characteristic tri-methyl guanosine Cap of snRNAs (TMG beads, Millipore) 
(Fig 8A). Endogenous SmN protein showed strong enrichment in the affinity purified snRNP 
samples, as expected for a core snRNP protein. Endogenous SMN was also co-enriched with 
snRNPs, demonstrating that the experimental conditions were suitable to identify proteins 
important for snRNP assembly as well as those that are genuine snRNP components. NCDN-GFP 
did not co-purify with splicing snRNPs, however, suggesting that NCDN is not involved in snRNP 
assembly or processing. This raises the intriguing possibility that the interaction between SMN and 
NCDN reflects a novel, snRNP-independent role for SMN.  
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SMN interacts with Rab5 in SH-SY5Y cells and co-localises with a sub-set of Rab5 vesicles. 
 
Recent studies have found that SMA may cause endocytic defects, especially in synaptic 
vesicle recycling in animal models (Dimitriadi et al., 2016). Several SMA-protective disease 
modifier genes, such as Plastin 3, Coronin 1C, and Neurocalcin Delta, are also associated with 
endocytosis (Hosseinibarkooie et al., 2016; Oprea et al., 2008; Riessland et al., 2017). However, 
other endocytic structures within the cell have not been investigated. Rab5 is a marker of early 
endosomes and endocytic vesicles, as well as being a regulator of these trafficking pathways (Bucci 
et al., 1992). NCDN and Rab5 have previously been shown to interact, while both Rab5 and NCDN 
both have roles in dendrite morphogenesis and cell polarity (Guo et al., 2016; Oku et al., 2013; 
Satoh et al., 2008). 
As we had previously shown that SMN and NCDN co-localise in vesicles, we hypothesised 
that some of the SMN-rich vesicles could be Rab5 vesicles. SH-SY5Y cells were co-transfected with 
plasmids to express mRFP-Rab5 (Vonderheit and Helenius, 2005) together with either GFP-SMN, 
NCDN-GFP or YFP. mRFP-Rab5 was affinity-purified from whole cell lysates from each co-
transfection using RFP-TRAP (Chromotek). Subsequent immunoblotting revealed co-purification of 
GFP-SMN and NCDN-GFP, but not YFP alone, with mRFP-Rab5 (Fig 8B). Furthermore, endogenous 
SMN also co-purified with mRFP-Rab5. In parallel experiments, co-localisation of mRFP-Rab5 with 
GFP-SMN and NCDN was investigated (Fig 8C,D). In accordance with previous publications, Rab5 
showed partial co-localisation with NCDN-GFP in cytoplasmic structures (arrows in Fig 8D) (Oku et 
al., 2013). GFP-SMN showed a similar degree of co-localisation with mRFP-Rab5, also in 
cytoplasmic structures, while there was minimal co-localisation between YFP and mRFP-Rab5. 
Taken together with the absence of NCDN from enriched snRNP fractions (Fig 8A), this suggests 
that NCDN and SMN co-localise in the context of Rab5 vesicles, independently of snRNP assembly. 
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Discussion 
 
The genetic cause of SMA has been known since 1995 (Lefebvre et al., 1995), but there is 
still little available in the way of treatment. Spinraza/Nusinersen is now available to treat SMA by 
correcting the defective splicing of the SMN2 transcript to promote production of full-length SMN 
protein. However, this is not a complete cure and requires regular maintenance doses through 
intrathecal injection. Additionally, little has been done to investigate potential symptoms that 
could arise later in life or in other tissues and organs in patients treated with Spinraza. Additional 
treatment options for SMA are still needed, for use in addition to Spinraza, or in place of it for 
patients for whom it is not suitable, including those with rarer forms of SMA in which SMN is not 
mutated. 
A significant reason for the lack of treatment options for SMA is uncertainty about the 
cellular roles of SMN, which appear to be numerous. In particular, it is not clear why motor 
neurones are so exquisitely sensitive to reduced levels of SMN when the key roles of the protein 
appear to be in pathways required in all cell types. By comparing the interactomes of two very 
similar members of Sm protein family, SmB and the neural-specific SmN, we have uncovered an 
interaction between SMN and the essential neural protein NCDN, which may be of relevance for 
SMA pathology and have the potential to open novel avenues for therapy development. 
 
The neural-specific Sm protein, SmN, behaves similarly to SmB, but shows subtle differences at 
the interactome level that may indicate alternative roles. 
 
Differences between members of the Sm protein family have not been systematically 
investigated, although non-splicing roles have been proposed for SmB and SmD3 in mRNA 
localisation and for SmD1 in miRNA biogenesis in Drosophila (Gonsalvez et al., 2010; Xiong et al., 
2015). As SmB and SmN are thought to perform the same primary function in snRNPs (Huntriss et 
al., 1993), it is currently unknown why SmN is expressed in neural tissues as well as, or instead of, 
SmB. Current research has suggested that the expression of SmN may cause tissue specific 
alternative splicing of pre-mRNA transcripts (Lee et al., 2014). However, an alternative, but 
complimentary hypothesis is that SmN may be adapted for secondary, neural specific roles. We 
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 demonstrate here that SmN localises identically to SmB during snRNP maturation and at steady-
state, when both localise to vesicles containing SMN in the cytoplasm and neurites of SH-SY5Y cells 
in addition to their canonical localisation to nuclear CBs and speckles. Our parallel proteomic study 
used SH-SY5Y neural cell lines constitutively expressing YFP-SmN and YFP-SmB to investigate 
difference between the interactomes of these two, very similar, proteins. SmN has a proline rich C-
terminal tail that SmB lacks, although a similar sequence is present in SmB’ (Mourao et al., 2016), 
an alternatively-spliced product of the SNRPB gene, which encodes SmB. Several proteins were 
identified in the SmN interactome but not the SmB interactome such as nuclear receptor co-
activator 6 interacting protein (UniProt Q96RS0), and 7SK snRNA methylphosphate capping 
enzyme (UniProt Q7L2J0), both of which are associated with snRNA capping (Hausmann et al., 
2008; Jeronimo et al., 2007). Additionally, RNA-binding protein 40 (UniProt Q96LT9) was uniquely 
identified within the SmN interactome, and is involved in the minor spliceosome (Benecke et al., 
2005). This suggests that some of these proteins may interact preferentially with SmN, perhaps 
mediated by amino acid changes within the proline-rich tail. However, further validation and 
additional experimentation would be required to confirm these differences in interactome 
between SmN and SmB and to investigate specific functions for the distinct Sm protein family 
members. 
 
NCDN interacts with SMN, SmB and SmN and co-localises with them in vesicles, suggesting a 
novel cellular role for SMN. 
 
Previous research into neural-specific functions for SMN has identified several new 
protein-protein interactions involving SMN. These novel SMN partners have, in the main, been 
RNA binding proteins (Akten et al., 2011; Fallini et al., 2014; Fallini et al., 2011; Rossoll et al., 
2003). There is growing appreciation that SMN-mediated transport may be of particular 
importance in neural cells and involve COP1-type vesicles transported by Dynein and containing 
SmB (Custer et al., 2013; Li et al., 2015; Peter et al., 2011; Prescott et al., 2014). The nature and 
content of these vesicles is not clear but they are likely to be of significance for the cell-type bias 
of SMA symptoms, as they are present predominantly in neural cells (Akten et al., 2011; Fallini et 
al., 2016; Fallini et al., 2014; Fallini et al., 2011; Li et al., 2015; Peter et al., 2011; Prescott et al., 
2014; Rossoll et al., 2003; Todd et al., 2010a; Todd et al., 2010b; Zhang et al., 2006; Zhang et al., 
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 2003). The SmN/SmB interactome screen presented here suggests a large number of non-snRNP 
proteins as potential cellular partners for the Sm proteins.  
We chose to investigate the neural protein NCDN further, as it has characteristics that may 
be of relevance for SMA. NCDN is predominantly expressed in neural tissue, and little is known 
about its structure or function, as it shares little sequence homology with other eukaryotic 
proteins (Shinozaki et al, 1997). Though characterised relatively poorly, it is associated with 
dendrite morphogenesis and localises to Rab5 vesicles involved in the maintenance of cell polarity 
(Guo et al., 2016; Oku et al., 2013), NCDN has also been demonstrated to regulate localisation of 
signalling proteins such as P-Rex 1 (Pan et al., 2016), suggesting that it, in common with SMN, has 
a role in intra-cellular trafficking. These neural-specific and trafficking roles suggest that further 
analysis of the interaction between NCDN and the Sm proteins may help to better understand the 
molecular mechanisms of pathogenesis in SMA. 
Reciprocal affinity-purification of GFP-tagged and endogenous NCDN and Sm proteins (Fig 
3A, B) validated the interaction detected in the interactome analysis. Although originally identified 
as a protein interacting with SmN but not SmB, further investigation indicates that NCDN is, in 
fact, capable of interacting with both of these Sm proteins. Of much greater interest, however, is 
the interaction documented between NCDN and SMN, which appears more robust than that 
between NCDN and the Sm proteins (Fig 3). Furthermore, NCDN localises with SMN and the Sm 
proteins in mobile vesicles in the neurites of SH-SY5Y cells (Fig 4), rather than in the nucleus, 
suggesting that it shares cytoplasmic, rather than nuclear, roles with SMN. The truncated protein 
SMN∆7, which can’t fully substitute for FL-SMN despite retaining some functionality, is largely 
restricted to the nucleus (Renvoise et al., 2006; Sleigh et al., 2011). While it can’t yet be ruled out 
that SMN∆7 lacks the capability to substitute for FL-SMN in nuclear roles, this suggests that 
cytoplasmic roles of SMN are key to SMA pathology. NCDN was not co-purified with splicing 
snRNPs, under conditions that showed a clear enrichment of SMN, a key assembly factor for 
snRNPs, in the snRNP fraction. This suggests that the interaction between NCDN, SMN and the Sm 
proteins is not related to snRNP assembly. 
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Potential consequences of NCDN mis-localisation associated with SMN reduction 
 
We have identified co-localisation of both SMN and NCDN with a sub-set of Rab5 vesicles. 
Since NCDN is also found in a sub-set of SMN-positive cytoplasmic structures, it is highly likely that 
these are Rab5 vesicles. It is possible that the protein-protein interactions between NCDN and 
SMN occur elsewhere in the cytoplasm as both proteins also show a diffuse cytosolic pool, but the 
decrease seen in cytoplasmic structures containing NCDN following SMN depletion suggest that 
cellular pathways requiring NCDN-containing vesicles may be compromised in SMA. Loss of NCDN-
positive cytoplasmic structures was seen in cells with a moderate reduction in SMN levels, so 
NCDN may be of relevance for patients with milder forms of SMA. 
At present, the precise roles of NCDN are not fully understood, although it has been 
implicated in dendrite morphogenesis, neural outgrowth, synaptic plasticity regulation, and 
moderation of signalling pathways in neural cells (Dateki et al., 2005; Francke et al., 2006; Matosin 
et al., 2015; Ohoka et al., 2001; Oku et al., 2013; Pan et al., 2016; Shinozaki et al., 1999; Shinozaki 
et al., 1997; Wang et al., 2013; Wang et al., 2009; Ward et al., 2009). NCDN has also previously 
been shown to localise to Rab5 vesicles within dendrites (Oku et al., 2013). These dendritic Rab5 
vesicles have been found have an important role in dendrite morphogenesis and somatodendritic 
polarity (Guo et al., 2016; Satoh et al., 2008). As we have now demonstrated that SMN localises to 
a sub-set of Rab5 vesicles, likely in association with NCDN, SMN may also be implicated in cell 
polarity, with an insufficiency of SMN causing problems with both establishment and maintenance 
of polarity. These would be particularly vital in such elongated cells as motor neurons and may be 
mediated through trafficking of mRNAs or proteins. Further work will be required to investigate 
defects in cell polarity as a pathogenic mechanism in SMA and their possible link to NCDN.  
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NCDN as a potential novel therapeutic target in SMA. 
 
SMN has now been linked to several functions other than its canonical role in snRNP 
assembly. While reduction in the cell’s capacity for snRNP assembly caused by lowered SMN may 
cause splicing defects, the key transcripts preferentially affecting motor neurones are still to be 
identified. SMN has an established role in the trafficking of mature mRNAs destined for localised 
translation. The nature of the structures involved in this role is not completely clear, however, 
with different authors describing the structures as vesicular or granular. Reduction of SMN has 
also been linked with endosomal defects, suggestive of the importance of SMN for vesicular 
transport. Here we provide further evidence for the presence of SMN in, or associated with, 
vesicles and document interactions between the essential neural protein, NCDN and SMN. 
Together with the clear enrichment of NCDN in motor neurones in mouse spinal cord, this 
suggests that NCDN may be a down-stream target of SMN reduction in SMA and places it as a 
potential target for therapy development in SMA. Further work will be required to establish which 
roles of NCDN also involve SMN, and whether these are of relevance for the molecular pathology 
of SMA. The co-dependence of SMN and NCDN in cytoplasmic vesicles, however, suggests that 
depletion of SMN, as seen in the majority of SMA patients, may affect NCDN localisation and/or 
function.   
 
Materials and Methods 
 
Plasmid constructs 
pEGFP-SMN, pEYFP-SmB and mCherry-SmB have been described previously (Clelland et al., 2009; 
Sleeman et al., 2001; Sleeman and Lamond, 1999). pEYFP-SmN and pmCherry-SmN were 
generated by PCR amplification and sub-cloning cDNA of human SmN from SH-SY5Y cells into 
pEYFP-C1 and pmCherry-C1 respectively, using SNRPNEcoRI forward primer: 
TAGAATTCCATGACTGTTGGCAAGAGTAGC, and SNRPNBamHI reverse primer: 
TAGGATCCCTGAGATGGATCAACAGTATG. pmCherry-SMN was generated by PCR amplification sub-
cloning the sequence from the pEGFP-SMN plasmid into pmCherry-C1 using an SMNEcoRI Forward 
primer: GCGGAATTCTATGGCGATGAGC and SMNBamHI Reverse Primer: 
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 GCAGGATCCTTAATTTAAGGAATGTGA. To generate pEGFP-NCDN, NCDN cDNA from SH-SY5Y cells 
was PCR amplified and sub-cloned into a pEGFP-N3 plasmid using NCDNEcoRI forward primer: 
GCGGAATTCATGGCCTCGGATTGCG and NCDNSalI reverse primer: GCTGCTGACGGGCTCTGACAGGC. 
All cDNAs were amplified using GoTaq G2 (Promega, Madison, WI, USA) and the PCR products 
restriction digested using EcoRI  and either BamHI or SalI (Promega), before ligation with T4 DNA 
ligase (Thermo Scientific, Waltham, MA, USA). mRFP-Rab5 was a gift from Ari Helenius (Vonderheit 
and Helenius, 2005). 
 
Cell lines and cell culture 
SH-SY5Y cells were from ATCC. Cells were cultured in DMEM with 10% FBS at 37°C, 5% CO2. 
Transfections were carried out using Effectene (Qiagen, Hilden, Germany) according to the 
manufacturer's instructions. Stable SH-SY5Y cell lines expressing mCherry–SmB and GFP–SMN 
have been described previously (Clelland et al., 2009; Prescott et al., 2014). SH-SY5Y cell lines 
stably expressing YFP-SmN, YFP-SmB, YFP, mCherry-SmN and NCDN-GFP were derived by clonal 
isolation following selection with 200 µg/ml G418 (Roche, Basel, Switzerland) following 
transfection.  
 
Animals 
Mouse tissues in this study were obtained from littermate, healthy control mice (Smn+/-; 
SMN2tg/0) from the ‘Taiwanese’ model of SMA.(Hsieh-Li et al., 2000) Mice were originally 
obtained from Jackson Laboratories and were maintained in animal care facilities at the University 
of Edinburgh under standard specic pathogen–free conditions on a congenic FVB background. All 
animal breeding was done in accordance with University of Edinburgh institutional guidelines and 
under the appropriate project and personal licenses granted by the UK Home Office.  
 
Immunostaining, microscopy and image analysis 
Cell fixing and immunostaining were both carried out as described previously (Sleeman et al., 
2003). Immunostaining of spinal cord sections was carried out as described previously (Powis and 
Gillingwater, 2016). Live cell and fixed cell microscopy and image processing were carried out as 
described previously (Prescott et al., 2014). BODIPY-493 (Life Technologies, Paisley, UK) was added 
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 to culture medium at 2 µg/ml overnight. Antibodies used for immunostaining were mouse 
monoclonal Y12 anti-Smith (SmB) (Abcam, Cambridge, MA, USA, ab3138, 1:20), rabbit polyclonal 
204-10 (anti-Coilin) (a gift from A. I. Lamond (Bohmann et al., 1995), 1:500), mouse monoclonal 
anti-SMN (BD Transduction, San Jose, CA, USA, 610646, 1:50), goat anti-ChAT (Millipore, 
Burlington, MA, USA, AB144P) and rabbit polyclonal anti-NCDN (Proteintech, Manchester, UK, 
13187-1-AP, 1:50). Overlays of images were made using Adobe Photoshop CS5 (Adobe, San Jose, 
CA, USA). Co-localisation images were generated using Volocity 6.3 (PerkinElmer, Waltham, MA, 
USA), using automatic thresholds on non-deconvolved images. Co-localisation values of 0.05 or 
less were excluded as this was the maximum co-localisation value observed between mCherry 
signal and YFP signal in neurites expressing YFP as a control together with mCherry-tagged 
proteins of interest. Deconvolution was also performed using Volocity 6.3, with between 15 and 
25 iterations of deconvolution. Images of spinal cord sections collected using a 60x objective on a 
DeltaVision RT microscope (Applied Precision) were assembled into panels using the FIJI 
(Schindelin et al., 2012) plug-in and a custom written export protocol. 
 
Statistical Analysis, and generation of graphs 
Data was processed using Microsoft Excel (Microsoft) to produce ratios, proportions and 
percentages. Bar charts, Box and Whisker plots were then generated using Prism 6 (GraphPad, La 
Jolla, CA, USA) from the processed data. Statistical analysis was also performed using Prism 6, with 
multiple comparisons to determine statistical difference between specific sets of data. Tukey post-
tests were used to identify outliers in Anova statistical analysis.  
 
Preparation of cell lysates and immunoblotting 
Cells were grown in 10cm diameter dishes, before being detached with trypsin and collected by 
centrifugation at 180 RCF for 5 minutes. The cell pellet was washed 3 times in PBS before lysis in 
100l of ice cold lysis buffer per dish (50 mM Tris-HCl pH 7.5; 0.5 M NaCl; 1% (v/v) Nonidet P-40; 
1% (w/v) sodium deoxycholate; 0.1% (w/v) SDS; 2 mM EDTA plus cOmplete mini EDTA-free 
protease inhibitor cocktail (Roche, one tablet per 10 ml)), followed by homogenisation by 
sonication. Isolation of YFP/GFP and mCherry/mRFP- tagged proteins was carried out as described 
previously with GFP- or RFP-Trap (Chromotek, Planegg-Martinsried, Germany)(Prescott et al., 
2014). Immuno-precipitation of endogenous SMN from brain lysate was carried out as described 
previously using mouse monoclonal anti-SMN (BD Transduction labs 610646) (Boyd et al., 2017; 
Groen et al., 2013). Lysates were electrophoresed on a 10% SDS-polyacrylamide gel and 
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 transferred to nitro-cellulose (Hybond-C+ or Protran premium 0.2m, both GE Healthcare, Little 
Chalfont, UK) membranes for immunoblotting. Antibodies used were rat monoclonal anti-RFP 
(Chromotek 5F8, 1∶500); goat polyclonal anti-γCOP (Santa Cruz, Dallas, TX, USA, sc-14167, 
1∶250), rabbit polyclonal anti-GFP (Abcam ab290, 1:2000), rabbit polyclonal anti-SNRPN (SmN) 
(Proteintech 11070-1-AP, 1:800), mouse monoclonal Y12 anti-Smith (SmB) (Abcam ab3138,  
1:100), rabbit polyclonal anti-SMN (Santa Cruz sc-15320, 1:500), mouse monoclonal anti-SMN (BD 
Transduction labs 610646, 1:500), rabbit polyclonal anti-COPB1 (CUSAB, College Park, MD, USA, 
CSB-PA005783LA01HU, 1:500), mouse monoclonal anti-Lamin A/C (Santa Cruz sc-7292, 1:500), 
rabbit polyclonal anti-NCDN (Proteintech 13187-1-AP, 1:500), mouse Monoclonal anti-tubulin 
(Sigma Aldrich, St Louis, MO, USA, 1:500) and rabbit polyclonal anti-Histone H3 (Proteintech 
17168-1-AP, 1:300). Secondary antibodies were goat anti-rabbit Dylight 700 (Thermo Scientific 
35569, 1:15,000) or goat anti-mouse Dylight 800 (Thermo Scientific SA5-10176, 1:15,000). 
Alternatively, goat anti-mouse IRDye 800CW (Li-Cor 925-32210, 1:25,000) and goat anti-rabbit 
IRDye 680RD (Li-Cor 925-68071, 1:25,000) were used. Goat anti-Rat Dylight 800 (Thermo Scientific, 
SA5-10024) antibody was used to visualise the rat monoclonal anti-RFP antibody at a 
concentration of 1:15,000. Donkey anti-goat IRDye 800CW (Licor, Lincoln, NE, USA, 925-32214) 
was used at a concentration of 1:25,000 to detect goat polyclonal anti-γCOP. Donkey anti-rabbit 
conjugated to horseradish peroxidase (HRP) (Pierce, Waltham, MA, USA, 31460, 1:15,000) was 
used to identify endogenous NCDN in figure 3D. Detection of antibodies conjugated to 
fluorophores was carried out with an Odessey CLx using Image Studio (both Li-cor). Band 
quantification was also performed using Image Studio. Detection of antibodies conjugated to 
peroxidase was performed using ECL Western Blotting Substrate (Pierce) and developed with 
Hyperfilm (Amersham), using a Kodak X-OMAT 1000 developer, after 30-45 minutes exposure.  
 
Immunoprecipitation of intact snRNPs 
To immunoprecipitate intact snRNPS, whole cell lysates were incubated with anti-2,2,7-
trimethylguanosine conjugated to agarose beads (Millipore NA02A), with Sepharose 4B beads 
(Sigma Aldrich) as a control. 40 ng of pre-cleared lysate and unbound protein were separated by 
SDS-PAGE alongside material precipitated with Sepharose control beads and TMG antibody beads. 
Subsequent detection was carried out using rabbit anti-GFP (1:2000, Abcam), rat mAb anti-RFP 
(1:500, Chromotek), mouse monoclonal anti-SMN (1:500, BD Transduction labs) and rabbit 
polyclonal anti-SNRPN (1:800, Proteintech).  
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Preparations and analysis of Mass Spectrometry samples 
SH-SY5Y cells constitutively expressing either YFP, YFP-SmN or YFP-SmB were lysed in co-
immunoprecipitation buffer (10mM Tris pH7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP40, 1 
cOmplete EDTA-free protease inhibitor tablet (Roche) per 10ml), followed by affinity purification 
of the tagged proteins with GFP-Trap as above. 11mg of total protein per sample was used as 
input. 5l of the affinity isolated material, alongside precleared lysate and unbound lysate was 
transferred to nitrocellulose membrane (as above) and immunodetected using Rabbit anti-GFP 
(Abcam) to confirm efficient immunoprecipitation. Samples were then electrophoresed on a 
NuPAGE 4-12% Bis-Tris Acrylamide gel (Novex, Waltham, MA, USA, NP0321), Coomassie stained 
using SimplyBlue SafeStain (Invitrogen, Paisley, UK), gel chunks excised and analysed by the Mass 
Spectrometry and Proteomics Facility at the University of St Andrews. 
The gel chunks were cut into 1 mm cubes. These were then subjected to in-gel digestion, using a 
ProGest Investigator in-gel digestion robot (Digilab, Hopkinton, MA, USA) using standard protocols 
(Shevchenko et al., 1996). Briefly, the gel cubes were destained by washing with MeCN and 
subjected to reduction with DTT and alkylation with IAA before digestion overnight with trypsin at 
37°C. The peptides were extracted with 10% formic acid, and the volume reduced to ~20ul by 
concentration in a speedvac (Thermo Scientific).  
The peptides were then injected onto an Acclaim PepMap 100 C18 trap and an Acclaim PepMap 
RSLC C18 column (ThermoFisher Scientific), using a nanoLC Ultra 2D plus loading pump and 
nanoLC as-2 autosampler (Eksigent). The peptides were eluted with a gradient of increasing 
acetonitrile, containing 0.1 % formic acid (2-20% acetonitrile in 90 min, 20-40% in a further 30 min, 
followed by 98% acetonitrile to clean the column, before re-equilibration to 2% acetonitrile). The 
eluate was sprayed directly into a TripleTOF 5600 electrospray tandem mass spectrometer (Sciex, 
Foster City, CA) and analysed in Information Dependent Acquisition (IDA) mode, performing 250 
msec of MS followed by 100 msec MS/MS analyses on the 20 most intense peaks seen by MS. The 
MS/MS data files generated were analysed using the ProteinPilot Paragon search algorithm v5.0.1 
(Sciex) against the NCBInr database (Nov 2012) restricting the search to Homo sapiens, with 
trypsin as the digestion enzyme and selecting cysteine alkylation with iodoacetamide, ‘Gel based 
ID’ as a ‘Special factor’, ‘Biological modifications’ as the ‘ID Focus’ and a ‘Thorough’ ‘Search effort’.  
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 ProteinPilot also performs a decoy database search to assess the False Discovery Rate. Protein 
identifications were accepted if they were identified by at least 2 peptides with the Detected 
Protein Threshold set at 0.05.  The data was also analysed via the ‘Create mgf file’ script in 
PeakView (Sciex) using the Mascot search algorithm (Matrix Science), against the NCBInr database 
(Oct 2014) restricting the search to Homo sapiens (284,317 sequences), trypsin as the cleavage 
enzyme and carbamidomethyl as a fixed modification of cysteines and methionine oxidation as a 
variable modification. The peptide mass tolerance was set to ± 0.05 Da and the MSMS mass 
tolerance to ± 0.1 Da. Scaffold viewer (version Scaffold_4.5.1, Proteome Software) was used to 
validate  the identifications from Mascot. Peptide identifications were accepted if they could be 
established at greater than 95.0% probability by the Peptide Prophet algorithm (Keller et al., 
2002). Protein identifications were accepted if they could be established at greater than 99.0% 
probability and contained at least 2 identified peptides.  Protein probabilities were assigned by the 
Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that contained similar peptides and 
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. 
Identified proteins affinity purified alongside YFP-SmB or YFP-SmN were discounted if they were 
additionally identified as being affinity purified with YFP, or if they were present within the 
Sepharose bead proteome (Trinkle-Mulcahy et al., 2008). The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaino et al., 2016) 
partner repository with the dataset identifier PXD008710. 
 
RNAi assays 
Reduction of protein expression using siRNA was achieved by transfecting the appropriate cell 
lines with siRNAs (Dharmacon, Lafayette, CO, USA) using Viromer Green (Lipocalyx GmbH, Halle 
(Saale), Germany) according to the manufacturer's instructions. Cells were lysed for assay by 
immunoblotting, or fixed with paraformaldehyde for fluorescence microscopy, 48 hours after 
transfection. Sequences used were SMN: CAGUGGAAAGUUGGGGACA; SmB, a mixture of 
CCCACAAGGAAGAGGUACU, GCAUAUUGAUUACAGGAUG, CCGUAAGGCUGUACAUAGU, 
CAAUGACAGUAGAGGGACC; NCDN, individually and a mixture of NCDN 18 
GUUCAUUGGUGACGAGAAA, NCDN 19 AGACCUCAUCCUUGCGUAA, NCDN 20 
AGGCCAAGAAUGACAGCGA, NCDN 21 GGCCAUUGAUAUCGCAGUU; negative control (siControl) 
targeting luciferase, UAAGGCUAUGAAGAGAUAC; positive control targeting Lamin A/C, 
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 GGUGGUGACGAUCUGGGCU; SiGlo Cyclophillin B to determine transfection efficiency,  
GGAAAGACUGUUCCAAAAA. Lysates were electrophoresed on an SDS-PAGE gel, transferred to 
nitrocellulose membrane, and immunodetected with antibodies to the above proteins. Band signal 
intensity determined with ImageStudio (Li-Cor), and the values were normalised to tubulin, 
following correction for background. Reduction of protein expression using shRNA was achieved 
by transfecting SH-SH5Y cell lines with pSUPER-GFP.Neo plasmids (Oligoengine, Seattle, WA, USA) 
expressing shRNA to SMN and Cyclophilin B, which have been described previously (Clelland et al., 
2012) using Effectene (QIAGEN). 
 
Fractionation 
Cells were pelleted from the appropriate cell line, and incubated in Buffer A (10mM HEPES pH7.9, 
1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 1 cOmplete EDTA-free protease inhibitor tablet per 10ml) 
for 5 minutes, before being Dounce homogenised 25 times using the tight pestle to disrupt the 
plasma membrane. This was then centrifuged at 300 RCF for 5 minutes to pellet the nuclei. The 
supernatant was removed, recentrifuged at 300 RCF to further remove nuclei, before the 
supernatant was centrifuged at 16,100 RCF for 30 minutes using a refrigerated 5415R Centrifuge 
(Eppendorf, Hamburg, Germany). The nuclei were resuspended in Buffer S1 (250mM Sucrose, 
10mM MgCl2), before this was layered over with Buffer S3 (880mM Sucrose, 0.5mM MgCl2). The 
nuclear pellet was then centrifuged at 2800 RCF for 10 minutes to wash and pellet the nuclei. The 
supernatant from the 16,100 RCF centrifugation was further centrifuged at 100,000 RCF using an 
Optima Max-XP ultracentrifuge with a TLA-110 Rotor (Beckman-Coulter, Brea, CA, USA) for 60 
minutes. The supernatant was removed and kept. The 16,100 and 100,000 RCF pellets were 
washed in Buffer A and centrifuged at 16,100 RCF for 30 minutes or 100,000 RCF for 1 hour 
respectively. Each pellet was then resuspended in lysis buffer (see above). To confirm efficient 
separation of cytoplasmic fractions from the nuclear fractions, Mouse anti-tubulin (Sigma Aldrich, 
1:500) and Rabbit polyclonal anti-Histone H3 (Proteintech, 1:300) antibodies were used. 
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Figures 
 
 
 
Figure 1: SmN exhibits similar behaviour to SmB in SH-SY5Y cells. A) SH-SY5Y cells transiently 
expressing YFP-SmN and fixed after 24, 48 and 72 hours show variations in distribution of the YFP-
SmN with time. Immunostaining with Y12 (red on overlay) and anti-coilin (white on overlay) shows 
splicing speckles (arrowheads) and Cajal Bodies (CBs, triangles) respectively. Images are 
deconvolved z-stacks with 0.2 m spacing. Bar=7m. B) SmN initially localises diffusely in the 
cytoplasm, before localising to speckles at the 48 and 72 hour time-points. 3 independent 
experiments, n=100 cells per experiment. Data shown is mean +/- SD). C) Western blot analysis of 
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 snRNPs immunprecipitated using TMG beads (left hand lane) confirms that both YFP-SmN 
(detected with anti-YFP, top row) and mCherry-SmN (detected with anti-mCherry, bottom row) 
are incorporated into snRNPs. D) mCherry-SmN cytoplasmic structures are mobile and stain with 
the lipophilic dye BODIPY 493. Arrows identify mCherry-SmN structures stained with BODIPY 493, 
triangles identify BODIPY 493-stained vesicles not containing mCherry-SmN. mCherry alone does 
not accumulate in BODIPY 493-stained vesicles. Cells were imaged approximately every 4 seconds 
for 9 minutes. Images are single deconvolved z-sections. Bar=7m. E) mCherry-SmN and GFP-SMN 
co-localise in cytoplasmic foci in SH-SY5Y cells (arrowheads in left hand panels), whereas YFP alone 
shows no accumulation in mCherry-SmN foci (triangles in right hand panels). White signal on the 
overlay indicates areas of co-localisation. Images are single deconvolved z-sections. Bar=7m. F) 
Comparison of the percentage of mCherry-SmN vesicles per cell co-localising with GFP-SMN to 
those showing co-incidental overlap with YFP alone confirms the co-localisation (unpaired 2 tailed 
t-test, p=<0.0001, n=5).  
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Figure 2: The interactomes of SmB and SmN are similar, but there are differences at the level of 
individual proteins. A) Immunoblot analysis confirms efficient affinity purification of YFP-SmN, 
YFP-SmB and YFP. 10% of the affinity purified material (left hand lane in each panel) was 
compared to 80g of precleared lysate (Input) and unbound material using anti-GFP. GFP-Trap 
effectively immunoprecipitated all three proteins. B) After processing the mass spectrometry data, 
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 and sorting identified proteins into groups based on Gene Ontology annotations, the interactomes 
of SmN and SmB are very similar. C) A comparison between the amino acid sequences of SmN and 
SmB reveals their similarity. Differences in amino acid sequence are in red. Sequences were from 
Uniprot (entries P63162 (SmN) and P14678-2 (SmB)). D) Neurochondrin (NCDN) was identified in 
the interactome of YFP-SmN, with 5 unique peptide hits encompassing 9% sequence coverage. 
Each Ion score (Mascot Ion Score) was above the threshold for peptide identity (Mascot Identity 
Score), with 2 out of the 5 identified peptides having a score of above double the threshold score. 
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Figure 3: NCDN interacts with SmN, SmB and SMN in cell lines and in vivo A) Affinity isolation of 
NCDN-GFP using GFP-Trap, detected with anti-GFP (top row) co-enriches mCherry-SmB, detected 
with anti-mCherry (bottom row) in transiently co-transfected SH-SY5Y cells B) In an SH-SY5Y cell 
line constitutively expressing NCDN-GFP, affinity isolation of NCDN-GFP, detected with anti-GFP 
(top row) co-enriches SMN, SmB, SmN and the Coatomer protein COP, all detected with 
antibodies against the endogenous proteins (as labelled). C) In an SH-SY5Y cell line constitutively 
expressing YFP, affinity isolation of YFP, detected with anti-GFP (top row) does not co-enrich SMN, 
SmB or COP, all detected with antibodies to the endogenous proteins (as labelled). D) In an SH-
SY5Y cell line constitutively expressing GFP-SMN, affinity isolation of GFP-SMN, detected with anti-
GFP (top row) co-enriches endogenous NCDN, detected with anti-NCDN (middle row). Endogenous 
SMN, detected with anti-SMN (bottom row) is also co-enriched. E) Immunoprecipitation of 
endogenous SMN co-enriches endogenous NCDN in SH-SY5Y cells. F) Immunoprecipitation of 
endogenous SMN from murine P8 brain lysate co-enriches NCDN. 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
 
Figure 4: NCDN colocalises with SmN and SMN in the cytoplasm but not the nucleus and is 
expressed in motor neurones in mouse spinal cord. A) NCDN-GFP and mCherry-SmN co-localise in 
vesicle-like structures (arrows) in neurites of SH-SY5Y cells constitutively expressing mCherry-SmN, 
and transiently expressing NCDN-GFP (left hand panels). White areas in the merged image show 
areas of co-localisation. Co-localisation images (bottom row) were generated in Volocity, using 
automatic thresholds on undeconvolved z-sections before excluding values below 0.05 (see 
material and methods). No co-localisation is seen in the same cell line transiently expressing YFP 
alone (right hand panel). Triangles show structures containing mCherry-SmN, but not YFP. B) 
mCherry-SMN and NCDN-GFP co-localise in vesicles (arrows) in the cytoplasm of co-transfected 
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 SH-SY5Y cells (left hand panels). White areas in the merged image show areas of co-localisation. 
Co-localisation images (bottom row) were generated as above. No co-localisation is observed 
between mCherry-SMN and YFP (triangles, right hand panels). Bar= 7m. C) NCDN forms nuclear 
foci (arrows) in the nuclei of a small proportion of SH-SY5Y cells (≤2%, 2 independent experiments, 
n=100 cells per experiment). These do not co-localise with nuclear foci stained with coilin 
(arrowheads, left hand panels) or SMN (arrowheads, right hand panels). D) NCDN (green) is 
expressed throughout the spinal cord, with increased expression in motor neurons (arrows), 
identified with anti-ChAT (magenta). Bar=500m. E) Higher magnification imaging confirms the 
presence of NCDN in ChAT-positive motor neurones (single deconvolved z-section). Bar=10m. 
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Figure 5: Detergent-free fractionation of SH-SY5Y cells reveals that SMN, coatomer proteins, 
NCDN, SmB and SmN are all enriched in the 100,000 RCF vesicle pellet. A) Immunoblotting of 
equal protein amounts from fractionated SH-SY5Y cells reveals that SMN (top row) is highly 
enriched in the 100,000 RCF pellet, with smaller amounts seen in the 16,100 RCF pellet and the 
nuclear pellet. The coatomer protein, COP (second row) is also enriched in the 100,00 RCF pellet 
as well as the 16,100 RCF pellet. Antibodies to histone H3 and tubulin confirm minimal nuclear 
contamination in cytoplasmic fractions, and minimal cytoplasmic contamination in the nuclear 
pellet, respectively. B) Quantitation of immunoblot analysis confirms that SMN is highly enriched 
in the 100,000 RCF pellet, with enrichment of Cop also seen. Histone H3 and tubulin are highly 
enriched in the nucleus and cytoplasm respectively. Quantitation of tubulin and histone H3 bands 
was from 7 immunoblots, with values from SMN and COP from 5 and 4 immunoblots 
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 respectively. C) Immunoblotting of equal protein amounts from fractionated SH-SY5Y cells 
constitutively expressing NCDN-GFP, YFP-SmB, YFP-SmN or YFP alone (all detected with anti-GFP) 
reveals that NCDN-GFP is enriched in the 100,000 RCF pellet, with smaller amounts seen in the 
16,100 RCF pellet and the cytosolic supernatant. YFP-SmB and YFP-SmN are both also found in the 
100,000 RCF pellet, in addition to the nuclear pellet and cytosolic supernatant. YFP alone is found 
almost exclusively in the cytosolic supernatant, with none detected in the 100,000 RCF or 16,100 
RCF pellets. D) Quantitation of the immunoblots in C) confirms the presence of NCDN-GFP, YFP-
SmB and YFP-SmN in the 100,000 RCF pellet, together with the restriction of YFP alone to the 
residual cytosolic supernatant. 
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 Figure 6: Reduction of endogenous NCDN using siRNA increases localisation of SMN to nuclear 
foci. A) Transfection of SH-SY5Y cells constitutively expressing GFP-SMN (Green) with siRNAs 
shows an increase in the number of SMN-positive nuclear foci (arrows) in cells transfected with 
siRNAs against NCDN or SmB and a decrease in the number of SMN-positive nuclear foci in cells 
transfected with siRNAs against SMN in comparison to cells transfected with non-targeting siRNAs 
(siControl)  or siRNAs against lamin A/C as a ’targeting’ control. Transfection of SH-SY5Y cells with 
a plasmid to express GFP-SMN∆7 also results in increased numbers of SMN-positive nuclear foci. 
Cell nuclei are stained with Hoescht 33342 (grey on images). Transfection efficiency with siRNAs 
was greater than 90%, measured by transfection with siGlo Cyclophillin B (not shown). Bar=7m. 
Images are deconvolved z-stacks taken with 0.2m spacing B) Quantitation of numbers of SMN-
positive nuclear foci per nucleus shows a significant increase following reduction of NCDN (10.2 ( 
4.1) with siNCDN 18, 10.4 ( 4.9) ) (Mean   Standard Deviation) with siNCDN 19, 9.9 ( 4.1) with 
siNCDN 20, 9.5 ( 3.6) with siNCDN 21 and 10.7 ( 4.6) with siNCDN pooled compared to 4.4 ( 
2.5) in cells treated with non-targeting siRNA (siControl) and 4.2 ( 2.3) in cells treated with siRNAs 
targeting lamon A/C (siLaminA/C) . Reduction of SmB also shows an increase in numbers of SMN-
positive nuclear foci (to 16.7 ( 6.8) with siSmB), while reduction of SMN leads to a decrease in 
numbers of SMN-positive nuclear foci (to 0.7 ( 1.4) with siSMN). Expression of GFP-SMN∆7 
results in an increase of numbers of SMN-positive nuclear foci to 18.2 ( 5.3). The difference 
between each siNCDN and controls is statistically significant (AVOVA; P<0.0001, n=150 from 3 
replicates). A Tukey post-test identified outliers (individual points marked on graph). C) 
Immunoblot analysis using antibodies to endogenous NCDN, SMN and SmB shows a reduction in 
expression of each of 40-60% compared to siControl cells, after signals were normalised to tubulin 
(see also Fig. S5). Reductions in protein expression compared to siControl siRNA are statistically 
significant (ANOVA; P<0.0001 for NCDN, Lamin A/C and endogenous SMN, P<0.001 for SmB, and 
P<0.01 for GFP-SMN, n=3). A Dunnett post-test identified the significance of the reduction 
compared to siControl. 
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Figure 7: Reduction of endogenous SMN causes a reduction in cytoplasmic NCDN foci in SH-SY5Y 
cells. A) SH-SY5Y cells were transfected with plasmids to express shRNAs targeting SMN (shSMN), 
Cyclophilin B (shCyclophilin) or with the empty pSuper GFP vector (not shown), fixed after 72 
hours, and immunostained for endogenous NCDN and SMN allowing detection of NCDN foci 
within the cytoplasm (arrowheads), as well as SMN-positive nuclear gems (identified with 
Triangles). Bar= 7m, images are single deconvolved z-sections B) The depletion of SMN results in 
a reduction in the number of NCDN foci present in the cytoplasm to 15.3 ( 7.2) (Mean  Standard 
Deviation) from 20.6 ( 12.0) and 19.5 ( 7.6) compared to cells transfected with either 
shCyclophilin B or the empty pSuper GFP vector respectively (ANOVA P<0.0005, n=64 from 3 
replicates). C) The depletion of SMN causes a reduction of nuclear gems to 0.17 ( 0.38) from 2.3 
( 0.84) or 3.0 ( 1.0) compared to cells transfected with shCyclophilin B or empty vector 
respectively confirming efficient reduction in SMN protein levels (ANOVA P<0.0001, n=30 from 3 
replicates).  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
 
Figure 8: NCDN does not co-purify with snRNPs, while NCDN and SMN interact with Rab5 and 
co-localise with a subset of Rab5 vesicles within neurites of SH-SY5Y cells. A) Incubation of 
whole-cell lysate from an SH-SY5Y cell line constitutively expressing NCDN-GFP with  agarose 
beads conjugated to antibodies against the tri-methyl guanosine cap (Me3Gppp) of snRNAs (TMG 
beads) affinity purifies snRNPs as evidenced by the enrichment of the core snRNP protein SmN 
(detected with anti-SmN, bottom row). The enriched snRNP fraction also contains SMN, which is 
essential for snRNP assembly. NCDN-GFP, however, does not co-enrich with snRNPs. Also shown is 
the core structure of mature snRNPs consisting of the heptameric Sm protein ring bound at the Sm 
binding site of snRNA, as well as the characteristic tri-methyl guanosine Cap of snRNAs (Me3Gppp) 
at the 5’ end. B) Affinity isolation of mRFP-Rab5 using RFP-Trap from cells co-transfected with 
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 plasmids to express mRFP-Rab5 together with NCDN-GFP, GFP-SMN or YFP alone co-enriches both 
NCDN-GFP (top row, detected with anti-GFP, band is present in RFP-Trap lane but not sepharose 
beads lane) and SMN-GFP (second row, detected with anti-GFP, band is present in RFP-Trap lane 
but not sepharose beads lane), but not YFP (third row, no band detected in RFP-Trap lane). 
Endogenous SMN (fourth row, detected with mouse anti-SMN) co-enriches with mRFP-Rab5 in all 
three samples. Detection of mRFP-Rab5 (bottom row, detected with anti-RFP) confirms robust 
enrichment of mRFP-Rab5 in all three samples. C) Both GFP-SMN and NCDN-GFP partially co-
localise with mRFP-Rab5 in a subset of mRFP-Rab5 containing vesicles in co-transfected SH-SY5Y 
cells (white signal in overlaid images, top row; yellow signal in co-localisation images, bottom 
row). D) Enlargement of the boxed areas in C) confirms that the co-localisation between 
SMN/NCDN and Rab5 occurs in punctate structures. Arrowheads identify areas of co-localisation. 
Co-localisation images were generated by Volocity, using automatic thresholds on non-
deconvolved z-sections before excluding values below 0.05. Images (excluding the co-localisation 
images) are single deconvolved z-sections. Bar=7m. 
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Figure	S1:	mCherry-SmN	exhibits	similar	behaviour	to	both	YFP-SmN	and	SmB	in	SH-SY5Y	cells.	
A) SH-SY5Y	cells	transiently	expressing	mCherry-SmN	and	fixed	after	24,	48	and	72	hours	show
variations	in	distribution	of	the	mCherry-SmN	with	time.	Immunostaining	with	Y12	(green	on	
overlay)	and	anti-coilin	(white	on	overlay)	shows	splicing	speckles	(arrowheads)	and	Cajal	Bodies	
(CBs,	triangles)	respectively.	Images	are	deconvolved	z-stacks	with	0.2	µm	spacing.	Bar=7µm.	B)	
mCherry-SmN	initially	localises	diffusely	in	the	cytoplasm,	before	localising	to	speckles	at	the	48	
and	72	hour	time-points.	3	independent	experiments,	n=100	cells	per	experiment.	Data	shown	is	
mean	±	SD.	
J. Cell Sci. 131: doi:10.1242/jcs.211482: Supplementary information
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Table	S2:	A	selected	dataset	from	the	interactome	analysis	of	SmN	and	SmB	confirms	efficient	
identification	of	known	Sm	protein	interactors.	All	other	core	Sm	family	proteins	were	identified	
in	the	interactome	analysis,	as	well	as	SMN,	all	Gemin	components	of	the	SMN	complex	and	
several	LSm	proteins,	including	LSm11	(found	only	in	the	U7	snRNP).	Additionally,	several	
members	of	the	methylosome,	where	SmB	post-translational	modifications	occur,	were	identified	
including	Protein	arginine	N-methyltransferase	5	(PRMT5).	Several	previously	identified	SmB	
interactors	(CD2	antigen	cytoplasmic	tail	binding	protein-2,	PERQ2,	WW	domain-binding	protein	4	
and	Formin	binding	protein	4)	(Bedford	et	al.	1998,	Bedford	et	al.	2000,	Kofler	et	al.	2004,	Kofler	et	
al.	2005)	were	identified	to	interact	with	at	least	one	of	the	proteins.	*	denotes	that	spectra	from	
SmN	were	pooled	with	those	from	SmB	by	Scaffold	due	to	sequence	similarity	in	the	majority	of	
the	proteins.	Neurochondrin,	and	other	proteins	discussed	are	also	shown	here.	Values	are	
number	of	unique	peptides	identified.	
	
J. Cell Sci. 131: doi:10.1242/jcs.211482: Supplementary information
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Figure	S3:	NCDN	and	SmB	co-localise	in	neurites	of	SH-SY5Y	cells	constitutively	expressing	
mCherry-SmB,	and	transiently	expressing	NCDN-GFP.	Arrows	identify	SmB	containing-vesicles	
with	NCDN	co-localisation.	Bar=	7µm,	images	are	single	deconvolved	z-sections.	Co-localisation	
images	were	generated	in	Volocity,	using	automatic	thresholds	on	non-deconvolved	z-sections	
(see	materials	and	methods).	
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Figure	S4:	Endogenous	SmB	fractionates	similarly	to	YFP-SmB	and	YFP-SmN,	present	in	the	100,000	RCF	
vesicle	fraction	in	and	highly	enriched	in	the	nuclear	pellet	of	fractionated	SH-SY5Y	cells.	The	gap	between	
bands	in	the	whole	cell	lysate	and	cell	fractions	signifies	omitted	lanes.	
	
	
Figure	S5:	Quantified	immunoblots	of	proteins	targeted	by	siRNA	in	SH-SY5Y	cells	from	Fig	5C.	
Equal	volumes	of	lysate	were	immunoblotted,	with	band	intensity	of	A)	GFP-SMN,	and	B)	SMN,	
NCDN,	SmB	(Y12)	and	lamin	A/C	quantified,	and	normalised	to	band	intensity	of	tubulin,	to	
determine	the	relative	levels	of	protein	expression.		
J. Cell Sci. 131: doi:10.1242/jcs.211482: Supplementary information
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Movie	S1:	punctate	structures	containing	mCherry-SmN	within	the	cytoplasm	of	SH-SH5Y	cells	
are	mobile.	Images	were	taken	every	~2	seconds	for	~150	seconds.	Movie	is	a	projection	of	3	
deconvolved	z-stacks	taken	with	0.5µm	spacing.	Bar=7µm.	
J. Cell Sci. 131: doi:10.1242/jcs.211482: Supplementary information
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